AMGN

AMGN Earnings Track Record: Strong Beats, Uneven Reactions

Over the last eight reported quarters, Amgen (AMGN) has beaten EPS estimates seven times, a beat rate of 88%, with an average earnings surprise of 9.4%. That is one of the more consistent fundamental records among large-cap biopharma names. Yet the market’s reaction has not always matched the headline beat. Across those same eight quarters, the average five-trading-day move after the report has been 2.95% higher, classified as an “up” post-earnings drift. That looks bullish on the surface, but the last four reports show a much messier story: the two largest EPS surprises produced immediate drawdowns, while other beats produced sharp rallies that held for several days.

Look at the most recent releases. On 2026-04-30, AMGN reported $5.15 versus a $4.77 estimate, an 8% beat, yet the stock fell 4.75% the next day and 4.96% over the following five trading days. The February 2026 quarter delivered $5.29 versus $4.73 (an 11.8% surprise) and the stock jumped 8.15% the next session, finishing the five-day window up 7.7%. The November 2025 release was even stronger on both counts: a $5.64 print versus a $5.02 estimate (12.4% surprise) drove an 8.15% next-day gain and a 14.07% five-day gain. But the August 2025 quarter, a $6.02 result against $5.28 (14% surprise), was followed by a 5.14% next-day drop and a 5.03% five-day decline. In other words, AMGN’s average beat has been about 9.4%, but the next day alone has ranged from roughly +8.15% to –5.14% over the last year.

Options-Flow Dynamics Around the 2026-08-04 Report

AMGN’s next scheduled report is 2026-08-04 after the close, with an official consensus EPS estimate of $5.62. Around that date, options markets will price in a specific implied earnings move, and that implied move is set against the stock’s realized history of roughly ±5% to ±8% in the session following the past four releases. Pricing tools will also show whether traders are leaning long or short via open interest in near-term calls and puts. Because AMGN’s average 5-day drift has been 2.95% up, directional positioning can become crowded into the report, which raises the risk of a “sell the fact” unwind even if results beat.

At the current snapshot of $385.16, the stock is above its 50-day EMA of $361.44 and carries an RSI of 64.6, meaning it enters the report with some technical momentum. Within the Healthcare/Drug Manufacturers – General sector, AMGN generally moves on relative pipeline updates and full-year guidance as much as on the EPS print itself. Watch whether options skew favors calls over puts or whether straddle buyers are paying up for volatility — those flow readings often matter more than the binary beat-or-miss outcome.

What a Disciplined Trader Watches

A disciplined trader treats AMGN’s 88% beat rate and 9.4% average surprise as a baseline, not a trade signal. The key lesson from the data is that the immediate price reaction has not reliably followed the earnings surprise: both an 8% beat and a 14% beat sold off in the days after reporting, while 11.8% and 12.4% beats produced strong continuation. With the next report set for 2026-08-04 after the close, traders typically compare the option-implied move to the realized post-earning moves — the ±5% to ±8% recent one-day range and the average five-day drift of 2.95% up — to judge whether the setup is priced too cheaply or too richly.

Post-release, watch whether the first hour’s direction holds into the close and whether the move extends or reverses by day five. Given the last two quarters’ pattern of high-magnitude surprises moving in opposite directions, a post-earnings position should be sized for volatility and monitored against the 50-day EMA at $361.44 and the current RSI level near 64.6. The historical drumbeat of beats is meaningful, but in this name the forward path is resolved by subsequent trading behavior, not by the EPS beat alone.

For a deeper dive into institutional expectations heading into the 2026-08-04 report, explore the full institutional verdict and compare it to the current analyst consensus of $5.62 EPS.